Tapewire

Nasdaq · USD

ROIV

Roivant Sciences Ltd.

Export transactions ↓
Tapewire entity
3185
SEC CIK
0001635088
Parsed reports
457

Last 12 months

Inside the activity.

0 purchase rows · 114 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025016
Dec 2025029
Jan 202601
Feb 2026020
Mar 202603
Apr 202603
May 202601
Jun 2026023
Jul 202601
Aug 202609
Sep 202606
Oct 202602

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 5, 2026 22:05 UTC Exercise / conversionStock Option (Right to Buy) · Derivative 17,750 $0.00 Strike: $4.46 $0.00
Disclosure

SEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · derivative · entry 4

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,416

Underlying: Common Stock · 17,750 shares

Expires 2032-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested.

Read SEC document
October 01, 2026 Filed Oct 5, 2026 22:05 UTC SaleCommon Shares 900 $36.57 $32,913.00
Disclosure

SEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · nonDerivative · entry 3

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,954

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
October 01, 2026 Filed Oct 5, 2026 22:05 UTC SaleCommon Shares 16,850 $36.08 $607,948.00
Disclosure

SEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · nonDerivative · entry 2

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,854

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
October 01, 2026 Filed Oct 5, 2026 22:05 UTC Exercise / conversionCommon Shares 17,750 $4.46 $79,165.00
Disclosure

SEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 21:37 UTC
Venker EricPresident & Immunovant CEO
Exercise / conversionStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001635088-26-000108 · wk-form4_1790977058.xml · derivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,644,834

Underlying: Common Stock · 200,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 21:37 UTC
Venker EricPresident & Immunovant CEO
SaleCommon Shares 200,000 $36.62 $7,324,000.00
Disclosure

SEC source: 0001635088-26-000108 · wk-form4_1790977058.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,599,154

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 21:37 UTC
Venker EricPresident & Immunovant CEO
Exercise / conversionCommon Shares 200,000 $3.85 $770,000.00
Disclosure

SEC source: 0001635088-26-000108 · wk-form4_1790977058.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,799,154

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 21:38 UTC
Sukhatme MayukhDirector · President & CIO
Tax withholdingCommon Shares 46,879 $36.57 $1,714,365.03
Disclosure

SEC source: 0001635088-26-000109 · wk-form4_1790977119.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,583,860

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
September 30, 2026 Filed Oct 3, 2026 01:00 UTC
Torti FrankPresident and Vant Chair
Tax withholdingCommon Shares 40,309 $36.57 $1,474,100.13
Disclosure

SEC source: 0001140361-26-038474 · form4.xml · nonDerivative · entry 1

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,495,893

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
September 30, 2026 Filed Oct 3, 2026 01:00 UTC
Gline MatthewDirector · CEO
Tax withholdingCommon Shares 76,171 $36.57 $2,785,573.47
Disclosure

SEC source: 0001140361-26-038475 · form4.xml · nonDerivative · entry 1

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,583,774

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
September 20, 2026 Filed Sep 23, 2026 01:00 UTC
Humes JenniferChief Accounting Officer
Tax withholdingCommon Shares 3,880 $39.77 $154,307.60
Disclosure

SEC source: 0001140361-26-037363 · form4.xml · nonDerivative · entry 1

Humes Jennifer · CIK 0002058012 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,419

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
September 20, 2026 Filed Sep 22, 2026 22:26 UTC Tax withholdingCommon Shares 2,129 $39.77 $84,670.33
Disclosure

SEC source: 0001635088-26-000104 · wk-form4_1790116002.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,681

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 22:56 UTC GrantStock Option (Right to Buy) · Derivative 10,531 $0.00 Strike: $39.57 $0.00
Disclosure

SEC source: 0001807359-26-000016 · wk-form4_1789772167.xml · derivative · entry 2

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,531

Underlying: Common Shares · 10,531 shares

Expires 2036-09-15

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 22:56 UTC GrantCommon Shares 5,054 $0.00 $0.00
Disclosure

SEC source: 0001807359-26-000016 · wk-form4_1789772167.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,954

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 22:57 UTC GrantStock Option (Right to Buy) · Derivative 10,531 $0.00 Strike: $39.57 $0.00
Disclosure

SEC source: 0001349297-26-000010 · wk-form4_1789772242.xml · derivative · entry 2

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,531

Underlying: Common Shares · 10,531 shares

Expires 2036-09-15

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 22:57 UTC GrantCommon Shares 5,054 $0.00 $0.00
Disclosure

SEC source: 0001349297-26-000010 · wk-form4_1789772242.xml · nonDerivative · entry 1

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,162

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:01 UTC GrantStock Option (Right to Buy) · Derivative 10,531 $0.00 Strike: $39.57 $0.00
Disclosure

SEC source: 0001209181-26-000007 · wk-form4_1789772501.xml · derivative · entry 2

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,531

Underlying: Common Shares · 10,531 shares

Expires 2036-09-15

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:01 UTC GrantCommon Shares 5,054 $0.00 $0.00
Disclosure

SEC source: 0001209181-26-000007 · wk-form4_1789772501.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,959

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:06 UTC
Oren IlanDirector
GrantStock Option (Right to Buy) · Derivative 10,531 $0.00 Strike: $39.57 $0.00
Disclosure

SEC source: 0001635088-26-000099 · wk-form4_1789772800.xml · derivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,531

Underlying: Common Shares · 10,531 shares

Expires 2036-09-15

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:06 UTC
Oren IlanDirector
GrantCommon Shares 5,054 $0.00 $0.00
Disclosure

SEC source: 0001635088-26-000099 · wk-form4_1789772800.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,680

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:12 UTC GrantStock Option (Right to Buy) · Derivative 10,531 $0.00 Strike: $39.57 $0.00
Disclosure

SEC source: 0001635088-26-000102 · wk-form4_1789773168.xml · derivative · entry 2

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,531

Underlying: Common Shares · 10,531 shares

Expires 2036-09-15

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:12 UTC GrantCommon Shares 5,054 $0.00 $0.00
Disclosure

SEC source: 0001635088-26-000102 · wk-form4_1789773168.xml · nonDerivative · entry 1

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,965,815

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 22:43 UTC SaleCommon Shares 600 $40.38 $24,228.00
Disclosure

SEC source: 0001807359-26-000014 · wk-form4_1789684991.xml · nonDerivative · entry 2

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,900

F2 · balance_after: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 22:43 UTC SaleCommon Shares 4,338 $39.65 $172,001.70
Disclosure

SEC source: 0001807359-26-000014 · wk-form4_1789684991.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,500

F1 · balance_after: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 22:42 UTC SaleCommon Shares 400 $40.45 $16,180.00
Disclosure

SEC source: 0001349297-26-000008 · wk-form4_1789684933.xml · nonDerivative · entry 2

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,108

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.28 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 22:42 UTC SaleCommon Shares 4,712 $39.68 $186,972.16
Disclosure

SEC source: 0001349297-26-000008 · wk-form4_1789684933.xml · nonDerivative · entry 1

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,508

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
September 10, 2026 Filed Sep 15, 2026 01:00 UTC Tax withholdingCommon Shares 5,133 $40.94 $210,145.02
Disclosure

SEC source: 0001140361-26-036535 · form4.xml · nonDerivative · entry 1

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,960,761

F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
September 10, 2026 Filed Sep 14, 2026 22:42 UTC
Oren IlanDirector
Tax withholdingCommon Shares 2,378 $40.94 $97,355.32
Disclosure

SEC source: 0001635088-26-000092 · wk-form4_1789425749.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,626

F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
September 10, 2026 Filed Sep 14, 2026 22:34 UTC Tax withholdingCommon Shares 2,179 $40.94 $89,208.26
Disclosure

SEC source: 0001807359-26-000012 · wk-form4_1789425238.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,838

F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
September 10, 2026 Filed Sep 14, 2026 22:29 UTC Tax withholdingCommon Shares 1,743 $40.94 $71,358.42
Disclosure

SEC source: 0001349297-26-000006 · wk-form4_1789424944.xml · nonDerivative · entry 1

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,220

F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
September 10, 2026 Filed Sep 14, 2026 22:25 UTC Tax withholdingCommon Shares 2,905 $40.94 $118,930.70
Disclosure

SEC source: 0001209181-26-000005 · wk-form4_1789424742.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,905

F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
September 08, 2026 Filed Sep 11, 2026 01:00 UTC Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $8.80 $0.00
Disclosure

SEC source: 0001140361-26-036246 · form4.xml · derivative · entry 3

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,578

Underlying: Common Stock · 20,000 shares

Expires 2033-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested.

Read SEC document
September 08, 2026 Filed Sep 11, 2026 01:00 UTC SaleCommon Shares 20,000 $39.90 $798,000.00
Disclosure

SEC source: 0001140361-26-036246 · form4.xml · nonDerivative · entry 2

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,963

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Read SEC document
September 08, 2026 Filed Sep 11, 2026 01:00 UTC Exercise / conversionCommon Shares 20,000 $8.80 $176,000.00
Disclosure

SEC source: 0001140361-26-036246 · form4.xml · nonDerivative · entry 1

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 28, 2026 Filed Sep 2, 2026 01:00 UTC
Venker EricPresident & Immunovant CEO
Exercise / conversionStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-035375 · form4.xml · derivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,844,834

Underlying: Common Stock · 200,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 28, 2026 Filed Sep 2, 2026 01:00 UTC
Venker EricPresident & Immunovant CEO
SaleCommon Shares 33,818 $36.44 $1,232,327.92
Disclosure

SEC source: 0001140361-26-035375 · form4.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,599,154

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

Read SEC document
August 28, 2026 Filed Sep 2, 2026 01:00 UTC
Venker EricPresident & Immunovant CEO
SaleCommon Shares 166,182 $35.63 $5,921,064.66
Disclosure

SEC source: 0001140361-26-035375 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,632,972

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

Read SEC document
August 28, 2026 Filed Sep 2, 2026 01:00 UTC
Venker EricPresident & Immunovant CEO
Exercise / conversionCommon Shares 200,000 $3.85 $770,000.00
Disclosure

SEC source: 0001140361-26-035375 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,799,154

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionStock Option (Right to Buy) · Derivative 144,756 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · derivative · entry 9

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,224,363

Underlying: Common Shares · 144,756 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 21, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
SaleCommon Shares 144,756 $36.48 $5,280,698.88
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 6

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 21, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionCommon Shares 144,756 $3.85 $557,310.60
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 5

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,775,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 20, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionStock Option (Right to Buy) · Derivative 17,519 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · derivative · entry 8

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,369,119

Underlying: Common Shares · 17,519 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 20, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
SaleCommon Shares 17,519 $37.30 $653,458.70
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 20, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionCommon Shares 17,519 $3.85 $67,448.15
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,648,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 20, 2026 Filed Aug 25, 2026 01:00 UTC Tax withholdingCommon Shares 5,749 $36.84 $211,793.16
Disclosure

SEC source: 0001140361-26-034239 · form4.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,810

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

F2 · balance_after: Includes Common Shares purchased under the Issuer's Employee Stock Purchase Plan.

Read SEC document
August 20, 2026 Filed Aug 25, 2026 01:00 UTC
Venker EricPresident & Immunovant CEO
Tax withholdingCommon Shares 13,909 $36.84 $512,407.56
Disclosure

SEC source: 0001140361-26-034238 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,599,154

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
August 19, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionStock Option (Right to Buy) · Derivative 172,899 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · derivative · entry 7

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,386,638

Underlying: Common Shares · 172,899 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 19, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
SaleCommon Shares 172,899 $37.17 $6,426,655.83
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 19, 2026 Filed Aug 22, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionCommon Shares 172,899 $3.85 $665,661.15
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,803,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 18, 2026 Filed Aug 19, 2026 01:00 UTC
Sukhatme MayukhDirector · President & CIO
Exercise / conversionCommon Shares · Derivative 136,942 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · derivative · entry 11

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,559,537

Underlying: Common Shares · 136,942 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.